1: Pouliquen DL, Malloci M, Boissard A, Henry C, Guette C.
Proteomes of Residual Tumors in Curcumin-Treated Rats Reveal Changes in Microenvironment/Malignant Cell Crosstalk in a Highly Invasive Model of Mesothelioma. Int J Mol Sci. 2022 Nov 8;23(22):13732. doi: 10.3390/ijms232213732. PMID: 36430209.
2 : Pouliquen DL, Boissard A, Henry C, Coqueret O, Guette C.
Curcuminoids as Modulators of EMT in Invasive Cancers: A Review of Molecular Targets With the Contribution of Malignant Mesothelioma Studies.
Front Pharmacol. 2022 Jul 8;13:934534. doi: 10.3389/fphar.2022.934534. PMID: 35873564; PMCID: PMC9304619.
3: Guillon J, Coquelet H, Leman G, Toutain B, Petit C, Henry C, Boissard A, Guette C, Coqueret O.
tRNA biogenesis and specific aminoacyl-tRNA synthetases regulate senescence stability under the control of mTOR.
PLoS Genet. 2021 Dec 20;17(12):e1009953. doi: 10.1371/journal.pgen.1009953. PMID: 34928935; PMCID: PMC8722728.
4 : Maarouf A, Boissard A, Henry C, Leman G, Coqueret O, Guette C, Lelièvre E.
Anterior gradient protein 2 is a marker of tumor aggressiveness in breast cancer and favors chemotherapy induced senescence escape.
Int J Oncol. 2022 Jan;60(1):5. doi: 10.3892/ijo.2021.5295. Epub 2021 Dec 16. PMID: 34913074; PMCID: PMC8727137.
5 : Pouliquen DL, Boissard A, Henry C, Blandin S, Coqueret O, Guette C.
Lymphoid Organ Proteomes Identify Therapeutic Efficacy Biomarkers Following the Intracavitary Administration of Curcumin in a Highly Invasive Rat Model of Peritoneal Mesothelioma.
Int J Mol Sci. 2021 Aug 9;22(16):8566. doi: 10.3390/ijms22168566. PMID: 34445271; PMCID: PMC8395293.
6 : Pouliquen DL, Boissard A, Henry C, Blandin S, Richomme P, Coqueret O, Guette C.
Curcumin Treatment Identifies Therapeutic Targets within Biomarkers of Liver Colonization by Highly Invasive Mesothelioma Cells-Potential Links with Sarcomas.
Cancers (Basel). 2020 Nov 16;12(11):3384. doi: 10.3390/cancers12113384. PMID: 33207594; PMCID: PMC7696465.
7 : Nader JS, Boissard A, Henry C, Valo I, Verrièle V, Grégoire M, Coqueret O, Guette C, Pouliquen DL.
Cross-Species Proteomics Identifies CAPG and SBP1 as Crucial Invasiveness Biomarkers in Rat and Human Malignant Mesothelioma.
Cancers (Basel). 2020 Aug 27;12(9):2430. doi: 10.3390/cancers12092430. PMID: 32867073; PMCID: PMC7564583.
8 : Pouliquen DL, Boissard A, Coqueret O, Guette C.
Biomarkers of tumor invasiveness in proteomics (Review).
Int J Oncol. 2020 Aug;57(2):409-432. doi: 10.3892/ijo.2020.5075. Epub 2020 May 28. PMID: 32468071; PMCID: PMC7307599.
9 : Nader JS, Guillon J, Petit C, Boissard A, Franconi F, Blandin S, Lambot S, Grégoire M, Verrièle V, Nawrocki-Raby B, Birembaut P, Coqueret O, Guette C, Pouliquen DL.
S100A4 is a Biomarker of Tumorigenesis, EMT, Invasion, and Colonization of Host Organs in Experimental Malignant Mesothelioma.
Cancers (Basel). 2020 Apr 10;12(4):939. doi: 10.3390/cancers12040939. PMID: 32290283; PMCID: PMC7226589.
10 : Jézéquel P, Patsouris A, Guette C, Juin PP, Campone M.
RE: Immune Checkpoint Profiles in Luminal B Breast Cancer (Alliance).
J Natl Cancer Inst. 2020 Aug 1;112(8):863-864. doi: 10.1093/jnci/djaa037. PMID: 32191300.
11 : Guillon J, Petit C, Toutain B, Guette C, Lelièvre E, Coqueret O.
Chemotherapy-induced senescence, an adaptive mechanism driving resistance and tumor heterogeneity.
Cell Cycle. 2019 Oct;18(19):2385-2397. doi: 10.1080/15384101.2019.1652047. Epub 2019 Aug 9. PMID: 31397193; PMCID: PMC6738909.
12 : Valo I, Raro P, Boissard A, Maarouf A, Jézéquel P, Verriele V, Campone M, Coqueret O, Guette C.
OLFM4 Expression in Ductal Carcinoma In Situ and in Invasive Breast Cancer Cohorts by a SWATH-Based Proteomic Approach.
Proteomics. 2019 Nov;19(21-22):e1800446. doi: 10.1002/pmic.201800446. Epub 2019 Aug 8. PMID: 31318138.
13 : Petit C, Guillon J, Toutain B, Boissard A, Patsouris A, Lelièvre E, Guette C, Coqueret O.
Proteomics Approaches to Define Senescence Heterogeneity and Chemotherapy Response.
Proteomics. 2019 Nov;19(21-22):e1800447. doi: 10.1002/pmic.201800447. Epub 2019 May 13. PMID: 30968557.
14 : Jézéquel P, Guette C, Lasla H, Gouraud W, Boissard A, Guérin-Charbonnel C, Campone M.
iTRAQ-Based Quantitative Proteomic Analysis Strengthens Transcriptomic Subtyping of Triple-Negative Breast Cancer Tumors.
Proteomics. 2019 Nov;19(21-22):e1800484. doi: 10.1002/pmic.201800484. Epub 2019 May 7. PMID: 30951236.
15 : Guillon J, Petit C, Moreau M, Toutain B, Henry C, Roché H, Bonichon-Lamichhane N, Salmon JP, Lemonnier J, Campone M, Verrièle V, Lelièvre E, Guette C, Coqueret O.
Regulation of senescence escape by TSP1 and CD47 following chemotherapy treatment.
Cell Death Dis. 2019 Feb 27;10(3):199. doi: 10.1038/s41419-019-1406-7. PMID: 30814491; PMCID: PMC6393582.
16 : Nader JS, Abadie J, Deshayes S, Boissard A, Blandin S, Blanquart C, Boisgerault N, Coqueret O, Guette C, Grégoire M, Pouliquen DL.
Characterization of increasing stages of invasiveness identifies stromal/cancer cell crosstalk in rat models of mesothelioma.
Oncotarget. 2018 Mar 27;9(23):16311-16329. doi: 10.18632/oncotarget.24632. PMID: 29662647; PMCID: PMC5893242.
17: Le Duff M, Gouju J, Jonchère B, Guillon J, Toutain B, Boissard A, Henry C, Guette C, Lelièvre E, Coqueret O.
Regulation of senescence escape by the cdk4-EZH2-AP2M1 pathway in response to chemotherapy.
Cell Death Dis. 2018 Feb 7;9(2):199. doi: 10.1038/s41419-017-0209-y. PMID: 29415991; PMCID: PMC5833455.
18 : Carné Trécesson S, Souazé F, Basseville A, Bernard AC, Pécot J, Lopez J, Bessou M, Sarosiek KA, Letai A, Barillé-Nion S, Valo I, Coqueret O, Guette C, Campone M, Gautier F, Juin PP.
BCL-X<sub>L</sub> directly modulates RAS signalling to favour cancer cell stemness.
Nat Commun. 2017 Oct 24;8(1):1123. doi: 10.1038/s41467-017-01079-1. PMID: 29066722; PMCID: PMC5654832.
